Clinical Trial

Phase 1B Trial of Intratumoral Cisplatin for Stage IV Lung Cancer

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The addition of intravenous (given through a vein) cisplatin to immunotherapy improves treatment outcomes for lung cancer, but unfortunately results in significantly more side effects since the rest of the body is exposed to significant amounts of the drug. Our clinical trial data indicate that injecting cisplatin directly into the tumor using a bronchoscope (a small flexible tube with a camera in it) has very few side effects, and results in significant cell death and potentially improvement in the immune response. The goal of this proposal is to evaluate a computational approach, that incorporates data from a CT scan, to determine the optimal dose and delivery location within a tumor to maximize tumor cell killing and the immune response.
Trial Details
NCT Number NCT07495098
Lead Sponsor University of Vermont
Conditions Lung Cancer Metastatic, Lung Cancer (NSCLC)
Enrollment 12 participants
Start Date 2026-07-01
Primary Completion 2030-07-01 (estimated)
Study Completion 2031-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-27